The nebulized Budezonide (pulmicort) effectiveness in acute adult asthma attack

Phase 2

• Conditions: asthma.; Severe persistent asthma with (acute) exacerbation; J45.51

• Registration Number: IRCT20170325033132N3
• Lead Sponsor: Astra Zeneca

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 26 March 2018

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

Age > 18 with signed informed consent letter
Patients with acute asthma(moderate to severe)

Exclusion Criteria

Unwillingness of patients to participate in the study
Patients with COPD
Pneumonia
Pneumothorax
CHF
Acute and severe respiratory failure with cyanosis and confusion
Loss of consciousness
Pregnant patients
Smokers
Intubated patients and patients with unstable vital signs
New case of asthma
Hemodynamic instability

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Improvement of vital sign and clinical symptoms in patients with asthma attack. Timepoint: At the begining of the study(before intervention), 30, 60, 180 minutes after treatment. Method of measurement: physical exam.

Secondary Outcome Measures

Name	Time	Method
Relief of acute asthma attack(sign and symptom)from patient and dr view. Timepoint: During the treatment in emergency center. Method of measurement: by completing questionnaire form, follow up, ask question about the number of readmission rate and length of hospitalization.